Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

Over the last several decades, mounting interest has positioned bioconjugate therapeutics as one of the most promising biopharmaceutical modalities. Work in chemical biology, including novel ...

Data supporting the rationale for Baylink's innovative ADC linker technology enabling delivery of degraders, dual payload antibody drug conjugates, and high drug to antibody ratio chemotherapy will be ...

- Lantern will evaluate and potentially develop ADC programs with novel patent protected linkers, drug payloads and conjugation processes from Califia that have demonstrated enhanced, highly targeted ...

MUNICH--(BUSINESS WIRE)--Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the ...

Traztuzumab deruxtecan (T-DXd) is the first antibody-drug conjugate (ADC) approved for lung cancer on the basis of activity in patients with HER2 mutation–positive non–small-cell lung cancer ...

NIJMEGEN, the Netherlands--(BUSINESS WIRE)--Synthon Biopharmaceuticals (‘Synthon’) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for its ...

One of the fastest-growing segments of pharmaceuticals, as highlighted at the 2024 J.P. Morgan Healthcare Conference, is the antibody-drug conjugate (ADC) segment. ADCs consist of four main elements: ...